AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02207517 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Office-based vergence/accommodative therapy
Description: The OBVAT program has been divided into 4 phases. Within each phase there are a number of categories such as gross convergence, vergence, and accommodation. The therapy procedures in each category have been arranged sequentially from easiest to most difficult
Study NCT02207517 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Office-based vergence/accommodative therapy
Description: The OBVAT program has been divided into 4 phases. Within each phase there are a number of categories such as gross convergence, vergence, and accommodation. The therapy procedures in each category have been arranged sequentially from easiest to most difficult
Study NCT00967213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: Lucentis® (ranibizumab) 0.3mg (0.05ml volume) intravitreal injection. Eligible patients will be initially received three session of monthly injection of Lucentis® (week 0, 4, 8). After 4 weeks from third injection, a session of verteporfin PDT (week 12) and fourth injection of Lucentis® (week 16) will be added at intervals of 4 weeks. Two more combined treatment with verteporfin PDT and Lucentis® injection 4 weeks apart can be added at the treating physician's discretion in 3-month intervals (week 28, week 40).
Study NCT01330693 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine
Description: Atomoxetine is FDA-approved for the treatment of ADHD symptoms in children. Single dose of 0.5 mg/kg at baseline visit. Then dose adjusted in an open-label design afterwards.
Study NCT01330693 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: In-active sugar pill randomly assigned at baseline visit
Study NCT04091360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A: RPL554
Description: Single dose RPL554 via metered dose inhaler.
Study NCT04091360 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Part A: RPL554
Description: Single dose RPL554 via metered dose inhaler.
Study NCT04091360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Part A: Single dose placebo via metered dose inhaler. Part B: Repeat doses of placebo via metered dose inhaler in crossover fashion. One dose administered twice daily over 7 days.
Study NCT04091360 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Part A: Single dose placebo via metered dose inhaler. Part B: Repeat doses of placebo via metered dose inhaler in crossover fashion. One dose administered twice daily over 7 days.
Study NCT04091360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B: RPL554
Description: Part B: Repeat doses via metered dose inhaler in crossover fashion. One dose administered twice daily over 7 days.
Study NCT03917641 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Khat leaves
Description: One of the two compressions (one per each eye) the patient will use will contain the Khat leaves.
Study NCT03813628 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: polished celtra press full coverage crown
Description: a full coverage crown in esthetic area made from celtra press ceramic( zirconia reinforced lithium silicate) and finished by just polishing
Study NCT03813628 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: glazed celtra press full coverage crowns
Description: a full coverage crown in esthetic area made from celtra press ceramic( zirconia reinforced lithium silicate) and finished by glazing
Study NCT03813628 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: contralateral natural teeth
Description: the polished and glazed all ceramic crowns will be compared by the contralateral natural teeth
Study NCT01998490 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Animal-assisted activity
Study NCT01998490 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robot-assisted activity
Study NCT02641249 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibration
Description: A device providing vibrations is placed on the subject and vibration is turned on and off in a 6 hour on/off sequence. Heart rate, respiratory pauses and oxygen saturation are compared during vibration (intervention) and without vibration (no intervention) in the same subject.
Study NCT01876563 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D
Description: one tab 4000 IU/day vitamin D
Study NCT01876563 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: one tab per day placebo
Study NCT00811421 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulphadoxine-pyrimethamine
Description: SP oral administration (500mg sulphadoxine and 25mg pyrimethamine) as IPTp at the 1st and 2nd Antenatal Clinic visit
Study NCT00811421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mefloquine (full dose)
Description: MQ oral administration (15 mg/Kg) on 1 day at the 1st and 2nd Antenatal Clinic visit as IPTp
Study NCT00811421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mefloquine (split dose)
Description: MQ oral administration (15 mg/kg) split dose over 2 days at the 1st and 2nd ANC visit as IPTp
Study NCT00811421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: MQ-placebo oral administration at the 1st, 2nd and 3rd Antenatal Clinic visit as IPTp
Study NCT00811421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mefloquine
Description: MQ oral administration (15 mg/Kg) at the 1st and 2nd Antenatal Clinic visit as IPTp
Study NCT02920151 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: balance exercises circuit
Description: Thirteen workstations were organized in a circuit format on involved multidirectional gait in different bases of support, unstable surfaces, functional reach, exercise with balls, and single-leg stance
Study NCT01615575 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transanal haemorrhoidal dearterialisation
Description: Closure of the arterial blood flow to the haemorrhoidal plexus, using a dedicated proctoscope with a Doppler probe, and a rectal mucopexy
Study NCT01615575 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stapler haemorrhoidopexy
Description: Haemorrhoidopexy with a single dedicated circular stapling device (PPH 03, Ethicon Endo-Surgery, Ohio, USA).
Study NCT04358796 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygent treatment
Description: Subjects will enter the oxygen chamber. ATA will be elevated to 2 ATA. They will breath 100% oxygen while solving cognitive tests designed to assess their cognitive capacities
Study NCT04358796 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control hyperbaric oxygen treatment
Description: Subjects will enter the oxygen chamber. ATA will be elevated to 1.2 ATA for a short while and the decreased back to 1 ATA. They will breath air while solving cognitive tests designed to assess their cognitive capacities
Study NCT01258660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EE 0.03 mg/DRSP 3 mg/Metafolin + folic acid placebo
Description: Combination EE/DRSP/ Metafolin \[0.030 mg ethinylestradiol (EE) + 3 mg drospirenone (DRSP) + 0.451 mg Metafolin\] given orally in a cyclic regimen for 24 weeks (6 cycles) in combination with folic acid placebo tablets (encapsulated). Each treatment cycle consisting of once daily hormone and Metafolin treatment for 21-days followed by once daily hormone free, Metafolin only regimen for 7 days. This phase was followed by 20 weeks (5 cycles) folate elimination phase consisting of oral administration of Yasmin alone.
Study NCT01258660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EE 0.03 mg/DRSP 3 mg (Yasmin) + folic acid
Description: Yasmin \[0.030 mg ethinylestradiol (EE) + 3 mg drospirenone (DRSP)\] in combination with folic acid tablets 0.4 mg (encapsulated), given orally in a cyclic regimen for 24 weeks (6 cycles). Each treatment cycle providing once daily hormone and folic acid treatment for 21 days followed by once daily hormone free, folic acid only regimen for 7 days (encapsulated). This phase was followed by 20 weeks (5 cycles) folate elimination phase consisting of oral administration of Yasmin alone.
Study NCT01015313 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intensive sodium management
Description: 1. dietary sodium restriction~2. avoiding positive sodium balance during dialysis by: aligning dialysate sodium with plasma sodium, avoiding sodium profiling, and avoiding saline solutions to treat intradialytic symptoms
Study NCT01356992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Drugs will be provided by the sponsor to the study's patients on the reference presentation: 40 mg/0.4mL, 60 mg/0.6 mL and 80 mg/0.8 mL (solution for injection of enoxaparin sodium, 1 mg/ kg Sanofi-Aventis) or Eurofarma enoxaparin sodium (1 mg/ kg). The patients will use the drug corresponding to the arm of the study to which they were allocated. The drug administration must be performed through subcutaneous via on the dose of 1 mg/kg every 12 hours for at least 2 days and kept until the patient is discharged.
Study NCT01356992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: Drugs will be provided by the sponsor to the study's patients on the reference presentation: 40 mg/0.4mL, 60 mg/0.6 mL and 80 mg/0.8 mL (solution for injection of enoxaparin sodium, 1 mg/ kg Sanofi-Aventis) or Eurofarma enoxaparin sodium (1 mg/ kg). The patients will use the drug corresponding to the arm of the study to which they were allocated. The drug administration must be performed through subcutaneous via on the dose of 1 mg/kg every 12 hours for at least 2 days and kept until the patient is discharged.
Study NCT03103230 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cortical magnetic stimulation
Description: Motor Evoked Potentials of lips and hand recorded after cortical magnetic stimulation
Study NCT04874324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WCK 2349 Oral
Description: 1 dose given orally twice daily at 12 hourly interval for five days.
Study NCT04874324 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral
Description: Subjects will receive matching placebo
Study NCT01216293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole
Description: Dexlansoprazole 60 mg capsules
Study NCT01216293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: Esomeprazole 40 mg capsules
Study NCT01216293 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-matching capsules
Study NCT04190147 — intervention group
Intervention type: OTHER
Intervention: Structural, functional and metabolic eye examinations
Description: Structural, functional and metabolic eye examinations
Study NCT02197832 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial biopsy
Description: The procedure was performed in a standard approach using a Pipelle catheter (Pipelle de Cornier, Laboratoire C.C.D., France). The pipelle catheter was introduced through the cervix up to the uterine fundus. The piston was drawn back to the end of the sheath to create a negative pressure. The sheath was rotated and moved back and forth between the fundus and internal os for at least 3-4 times before it was gently withdrawn.
Study NCT02197832 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: control procedure
Description: Using pipelle catheter without entering the uterine cavity.
Study NCT02197832 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Pipelle catheter (Pipelle de Cornier, Laboratoire C.C.D., France)
Study NCT03326349 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guttmann, NeuroPersonalTrainer
Description: Guttmann NeuroPersonalTrainer (GNPT) is a telerehabilitation platform. GNPT consists of a set of computerized cognitive exercises covering different cognitive functions and subfunctions. Every task has been specifically based on cognitive paradigms to address specific cognitive subfunction. The rehabilitation process starts by assigning a patient to a therapist responsible for the treatment. The therapist has then to perform the initial neuropsychological assessment, consisting of a set of validated tests used to attention, memory and executive functions prior to the treatment. The results of these tests will be stored in GNPT system. Then, the cognitive profile is calculated using these results, and taking into account the patient's age and study level. Using this profile, the program assigns a set of computerized tasks to a certain day, configuring the input parameters of each task in order to personalize treatments.
Study NCT03326349 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Ictus.online
Description: An online domain which provides a daily session of one hour of duration. Each session consists of four ten-minute videos. After each video, the participant must complete a three-question quiz about the contents of the video (for example, What animal appears in in the video?). The difficulty level is minimal, and does not vary depending on the execution of the participant.
Study NCT03853317 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: For the treatment of adults and pediatric patients 12 years and older with Metastatic Merkel Cell Carcinoma (MCC).
Study NCT03853317 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N-803
Description: Recombinant human super agonist interleukin-15 (IL-15) complex
Study NCT03853317 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: haNK™
Description: haNK™ for Infusion is a human, allogeneic, NK cell line that has been engineered to produce endogenous, intracellularly retained IL-2 and to express CD16, the high-affinity (158V) Fc gamma receptor (FcγRIIIa/CD16a).
Study NCT03934632 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Postabsorptive
Description: Saline will be infused to mimic postabsorptive circulating amino acid concentrations
Study NCT03934632 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Postprandial
Description: An amino acid infusate will be administered to mimic postprandial circulating amino acid concentrations
Study NCT03934632 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immobilisation
Description: One leg will undergo 2 days immobilisation prior to the test day
Study NCT01048606 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo + exercise
Description: Placebo: Non-active capsules of the same size and appearance than phytoestrogens capsules will be used as a placebo (same posology, i.e. 4 caps/day)~Exercise intervention: Three weekly 1h-sessions will be held on 3 non-consecutive days. Each session comprises a total of 60 min of aerobic exercise (on an ergometer device) and resistance exercise (with elastic bands, free weights, exercise ball, etc.), and a 5-min cool down. Cues regarding exercise intensity will be offered to maintain intensity in a range of 60 to 80% of maximal heart rate (with the use of a target pulse, etc.). The exercise sessions will be led by a physical activity specialist.
Study NCT01048606 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Phytoestrogens without exercise
Description: Phytoestrogens: The phytoestrogen supplements will consist of 70 mg/day of soy isoflavones taken as 4 caps/day. More specifically, the daily dose of isoflavones contains 44 mg of diadzein, 16 mg of glycitein and 10 mg of genestein extracted from natural soy.~Without exercise: participants will be asked to do only their usual activities without being involved in any kind of structured exercise sessions.
Study NCT01048606 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phytoestrogens + exercise
Description: Phytoestrogens: The phytoestrogen supplements will consist of 70 mg/day of soy isoflavones taken as 4 caps/day. More specifically, the daily dose of isoflavones contains 44 mg of diadzein, 16 mg of glycitein and 10 mg of genestein extracted from natural soy.~Exercise intervention: Three weekly 1h-sessions will be held on 3 non-consecutive days. Each session comprises a total of 60 min of aerobic exercise (on an ergometer device) and resistance exercise (with elastic bands, free weights, exercise ball, etc.), and a 5-min cool down. Cues regarding exercise intensity will be offered to maintain intensity in a range of 60 to 80% of maximal heart rate (with the use of a target pulse, etc.). The exercise sessions will be led by a physical activity specialist.
Study NCT01455792 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsies using image fusion
Description: MRI and soft image fusion guided biopsy
Study NCT01455792 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsies using image fusion
Description: MRI and soft image fusion guided biopsy
Study NCT01455792 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gold standard biopsy
Description: Gold standard TRUS biopsy
Study NCT00344006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chlorproguanil-dapsone-artesunate
Study NCT00344006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine
Study NCT02110524 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Transluminal Angioplasty
Study NCT02918240 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Appointment intervals
Study NCT02918240 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fixed orthodontic braces
Study NCT00273559 — intervention group
Intervention type: DRUG
Intervention: prednisone
Description: group 2 will remain on 5 mg of prednisone for at least 90 days post transplant.
Study NCT01971190 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal Aflibercept injection
Description: 2mg intravitreal Aflibercept(Eylea) injection at baseline, at 1 month, and at 2 month.~At 3 month, 4 month, 5 month, and 6 month, PRN treatment of aflibercept injection or half-fluence photodynamic therapy may be done, if one of following conditions is fulfilled.~The PRN treatment method was decided by investigator's discretion.~Of patient who had persistent intra- or subretina fluid on SD-OCT~1. Central subfield thickness is not decreased to more than 50 micrometer compared with baseline central subfield thickness~2. Best-corrected ETDRS letter score dose not increased more than 5 letters than baseline (because of the persistent CSC).~3. Central subfield thickness is thicker than the previous exam~4. BCVA letter score is worse than the previous exam (because of the persistent CSC)
Study NCT01971190 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham injection
Description: Sham injection at baseline, at 1 month, and at 2 month.~At 3 month, 4 month, 5 month, and 6 month, PRN treatment of aflibercept injection or half-fluence photodynamic therapy may be done, if one of following conditions is fulfilled.~The PRN treatment method was decided by investigator's discretion.~Of patient who had persistent intra- or subretina fluid on SD-OCT~1. Central subfield thickness is not decreased to more than 50 micrometer compared with baseline central subfield thickness~2. Best-corrected ETDRS letter score dose not increased more than 5 letters than baseline (because of the persistent CSC).~3. Central subfield thickness is thicker than the previous exam~4. BCVA letter score is worse than the previous exam (because of the persistent CSC)
Study NCT01971190 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Half-fluence photodynamic therapy
Description: At 3 month, 4 month, 5 month, and 6 month, PRN treatment of aflibercept injection or half-fluence photodynamic therapy may be done, if one of following conditions is fulfilled.~The PRN treatment method was decided by investigator's discretion.~Of patient who had persistent intra- or subretina fluid on SD-OCT~1. Central subfield thickness is not decreased to more than 50 micrometer compared with baseline central subfield thickness~2. Best-corrected ETDRS letter score dose not increased more than 5 letters than baseline (because of the persistent CSC).~3. Central subfield thickness is thicker than the previous exam~4. BCVA letter score is worse than the previous exam (because of the persistent CSC)
Study NCT01971190 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Half-fluence photodynamic therapy
Description: At 3 month, 4 month, 5 month, and 6 month, PRN treatment of aflibercept injection or half-fluence photodynamic therapy may be done, if one of following conditions is fulfilled.~The PRN treatment method was decided by investigator's discretion.~Of patient who had persistent intra- or subretina fluid on SD-OCT~1. Central subfield thickness is not decreased to more than 50 micrometer compared with baseline central subfield thickness~2. Best-corrected ETDRS letter score dose not increased more than 5 letters than baseline (because of the persistent CSC).~3. Central subfield thickness is thicker than the previous exam~4. BCVA letter score is worse than the previous exam (because of the persistent CSC)
Study NCT03965819 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pain Bloc-R
Description: Herbal Supplement containing Vit D3, Vit B6, Vit B12, White Willow Bark, Angelica Root, Acetyl L-carnitine HCl, Caffeine, L-Theanine, Benfotiamine, and L-Tetrahydropalmatine
Study NCT03965819 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Comparator - Acetaminophen
Description: DIN 02447479 Encapsulated for Blinding Purposes
Study NCT03965819 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: No active ingredients
Study NCT00779584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8776
Description: IV infusion